Myeloma and Monoclonal Gammopathy

Multiple myeloma is the second most common hematological neoplasm and despite therapeutic advances over the last ten years, it remains incurable for most patients. It is a unique cancer model used to research mechanisms that regulate malignant transformation from a benign stage called "monoclonal gammopathy of undetermined significance (MGUS)" to an indolent stage that progresses to a more advanced and active form of the disease: symptomatic multiple myeloma.

Multiple myeloma is a singular model in that different clinical stages have a common denominator: the clonal plasma cell. This same common denominator is shared with other monoclonal gammopathies such as primary systemic amyloidosis and is characterized by the spread of a small clone of aberrant plasma cells.

Our line of research is cross-sectional between multiple myeloma and other monoclonal gammopathies. It has the following objectives:

  1. Characterization of the tumor cell based on preclinical models and clinical trials and identification of resistance biomarkers and potential therapeutic targets.

  2. Development of new ultra-sensitive methods for monitoring minimal residual disease.

  3. Characterization of primary systemic amyloidosis, clinical manifestations and disease prognosis.



"One of our areas of research focuses on identifying resistance biomarkers and potential therapeutic targets for multiple myeloma" , Dr. Jesús San Miguel, Principal Investigatorl

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es